Evidence map›Paper›PMID 40274757›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025

Engineering a multi-epitope chimera derived from Acinetobacter baumannii CAM87009.1 and FilF fimbriae proteins: immunogenic and antibiofilm activity.

Pamela Scaraffuni Caballero, Isabel Ladeira Pereira, Stella Buchhorn de Freitas, Alessandra Neis, Thayná Laner Cardoso, Daniela Rodriguero Wozeak, Amilton Clair Pinto Seixas Neto, Luciano da Silva Pinto, Daiane Drawanz Hartwig

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pamela Scaraffuni CaballeroBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil.
Isabel Ladeira PereiraBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil.
Stella Buchhorn de FreitasBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil.
Alessandra NeisBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil.
Thayná Laner CardosoBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil.
Daniela Rodriguero WozeakBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil.
Amilton Clair Pinto Seixas NetoBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil.
Luciano da Silva PintoBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil.
Daiane Drawanz HartwigBiotechnology Unit, Center of Technological Development, Federal University of Pelotas, Pelotas, RS, CEP 96010-900, Brazil. daianehartwig@gmail.com.ORCID http://orcid.org/0000-0003-3604-0832

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível Superior Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação de Amparo à Pesquisa do Estado do Rio Grande do Sul Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
6 · The paper itself

Abstract

This study aimed to develop a multi-epitope recombinant chimera (rChimera) based on two outer membrane proteins of Acinetobacter baumannii, targeting passive or active immunization strategies against biofilm-forming strains of this multidrug-resistant bacterium. Using bioinformatics and reverse vaccinology, we identified CAM87009.1 and FilF as two conserved proteins involved in biofilm formation and host cell adherence. An in silico analysis was performed to design the rChimera, selecting 36 promising B- and T-cell epitopes, including those recognized by MHC class I and II. These epitopes were linked using a glycine linker (GGGG) and a rigid linker (EAAKEAAAKA). The chimera was chemically synthesized, successfully expressed in Escherichia coli BL21 Star, and recognized by antibodies from naturally infected patients. Polyclonal antibodies (pAbs) produced in a murine model elicited a significant IgG response from the 14th day after the first immunization, with IgG1 and IgG2 (a and b) being the predominant isotypes generated. Anti-rChimera pAbs effectively inhibited biofilm formation in multidrug-resistant isolates and the ATCC® 19,606 strain of A. baumannii. The recombinant chimera shows promise for passive or active immunization against biofilm-forming strains of A. baumannii.

Indexed as

Acinetobacter baumanniiBiofilmsEpitopesFimbriae ProteinsAcinetobacter InfectionsAnimalsAntibodies, BacterialBacterial VaccinesFemaleHumansMiceMice, Inbred BALB CRecombinant Fusion ProteinsAntibodies, BacterialBacterial VaccinesEpitopesFimbriae ProteinsRecombinant Fusion ProteinsBiofilmEpitopesMulti-drug resistancepAbs

Identifiers

PMID40274757
PMCPMC12095767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.